GPCR Therapeutics Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
14
- Latest Deal Type
-
IPO
- (Cancelled)
- Investors
-
27
GPCR Therapeutics General Information
Description
Developer of pharmaceuticals designed to treat diseases and symptoms that do not have proper treatment. The company's products include innovative therapeutics targeting cancer-based on novel science of heteromers, enabling patients to address unmet medical needs for the treatment of cancer.
Contact Information
Website
gpcr.co.krCorporate Office
- Room 407, Nakseongdae R&D Center 38
- Nakseongdae-ro
- Seoul, Gwanak 08790
- South Korea
Corporate Office
- Room 407, Nakseongdae R&D Center 38
- Nakseongdae-ro
- Seoul, Gwanak 08790
- South Korea
GPCR Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. IPO | 01-Jun-2024 | Cancelled | Clinical Trials - Phase 2 | |||
| 7. Later Stage VC | 28-Nov-2023 | Completed | Clinical Trials - Phase 2 | |||
| 6. Secondary Transaction - Private | 28-Oct-2021 | Completed | Clinical Trials - Phase 2 | |||
| 5. Later Stage VC | 30-Jun-2021 | Completed | Clinical Trials - Phase 2 | |||
| 4. Later Stage VC (Series B) | 31-Jul-2019 | Completed | Startup | |||
| 3. Early Stage VC (Series A) | 30-Sep-2016 | Completed | Startup | |||
| 2. Accelerator/Incubator | 01-Oct-2015 | $2.1M | Completed | Startup | ||
| 1. Seed Round | 30-Sep-2015 | $2.1M | $2.1M | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
GPCR Therapeutics Comparisons
Industry
Financing
Details
GPCR Therapeutics Competitors (4)
One of GPCR Therapeutics’s 4 competitors is BioLineRx, a Formerly VC-backed company based in Modiin, Israel.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BioLineRx | Formerly VC-backed | Modiin, Israel | ||||
| TME Pharma | Formerly VC-backed | Berlin, Germany | ||||
| X4 Pharmaceuticals | Formerly VC-backed | Boston, MA | ||||
| Sanofi | Corporation | Gentilly, France |
GPCR Therapeutics Patents
GPCR Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026020039-A1 | Cxcr4 inhibitors and/or beta adrenergic receptor inhibitors for mobilization of lymphocytes andimmune cells | Pending | 18-Jul-2024 | ||
| AU-2024334309-A1 | Gpcr inhibitors and uses thereof | Pending | 30-Aug-2023 | ||
| EP-4770661-A2 | Gpcr inhibitors and uses thereof | Pending | 30-Aug-2023 | ||
| WO-2025050038-A2 | Gpcr inhibitors and uses thereof | Inactive | 30-Aug-2023 | ||
| WO-2025050038-A3 | Gpcr inhibitors and uses thereof | Inactive | 30-Aug-2023 | A61P35/00 |
GPCR Therapeutics Signals
GPCR Therapeutics Investors (27)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Friend Investment Partners (Seoul) | Venture Capital | Minority | ||
| LSK Investment | Venture Capital | Minority | ||
| Medytox Venture Investment | Corporate Venture Capital | Minority | ||
| Midasdong-a Investment | Venture Capital | Minority | ||
| Pharos Asset Management | Corporation | Minority |
GPCR Therapeutics Investments (2)
GPCR Therapeutics’s most recent deal was a PIPE with Parataxis Korea for . The deal was made on 22-Jan-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Parataxis Korea | 22-Jan-2024 | PIPE | Other Financial Services | ||
| GPCR Therapeutics (GPC-100 (Rights) in Taiwan) | 01-Nov-2020 | Corporate Asset Purchase | Buildings and Property |
GPCR Therapeutics FAQs
-
When was GPCR Therapeutics founded?
GPCR Therapeutics was founded in 2013.
-
Where is GPCR Therapeutics headquartered?
GPCR Therapeutics is headquartered in Seoul, South Korea.
-
What is the size of GPCR Therapeutics?
GPCR Therapeutics has 14 total employees.
-
What industry is GPCR Therapeutics in?
GPCR Therapeutics’s primary industry is Drug Discovery.
-
Is GPCR Therapeutics a private or public company?
GPCR Therapeutics is a Private company.
-
What is GPCR Therapeutics’s current revenue?
The current revenue for GPCR Therapeutics is .
-
How much funding has GPCR Therapeutics raised over time?
GPCR Therapeutics has raised $56.1M.
-
Who are GPCR Therapeutics’s investors?
Friend Investment Partners (Seoul), LSK Investment, Medytox Venture Investment, Midasdong-a Investment, and Pharos Asset Management are 5 of 27 investors who have invested in GPCR Therapeutics.
-
Who are GPCR Therapeutics’s competitors?
BioLineRx, TME Pharma, X4 Pharmaceuticals, and Sanofi are competitors of GPCR Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process